1. Home
  2. Live Updates
  3. Inhibrx inc

Live Breaking News & Updates on Inhibrx inc

Stay informed with the latest breaking news from Inhibrx inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Inhibrx inc and stay connected to the pulse of your community

Inhibrx, Sanofi ratify $2.2B deal for AATD therapy

Inhibrx Inc. and Sanofi SA have agreed to a deal worth up to $2.2 billion, whereby the latter’s Aventis Inc. subsidiary will acquire INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy undergoing a registrational trial for AAT deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants in the SERPINA1 gene.

Aventis-inc , Inhibrx-inc , Inhibrx-inc- , Sanofi-sa , Inbrx-101 , Aventis-inc- , Alpha-1-antitrypsin-deficiency , Bioworld , Deals-andm-amp-a , Respiratory , Aat-deficiency

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

United-states , Japan , Canada , American , Chiesi-farmaceutici , Mark-lappe , Inhibrx-inc , Exchange-commission , Prnewswire-inhibrx-inc , Nasdaq , European-medicines-agency , North-american

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...

Canada , United-states , Chiesi-farmaceutici , Drug-administration , Exchange-commission , Inhibrx-inc , Prnewswire-inhibrx-inc , Nasdaq , European-medicines-agency , Bristol-myers-squibb-company , European-union , Fast-track

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong...

Chiesi-farmaceutici , Exchange-commission , Prnewswire-inhibrx-inc , Bristol-myers-squibb-company , Inhibrx-inc , Nasdaq , Hepatic-steatosis-index , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act , Media-contact

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

/PRNewswire/ -- NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for...

Paul-estrem , Stephen-merrick , Lisa-holst , Priscilla-harlan , Exchange-commission , Prnewswire-northstar-medical-radioisotopes , Northstar-radiopharmaceutical-contract-development , Inhibrx-inc , Nasdaq , Northstar-medical-radioisotopes , Manufacturing-organization , Star-medical-radioisotopes

Inhibrx Announces Participation in Upcoming Investor Conference

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

Bristol-myers-squibb , Prnewswire-inhibrx-inc , Inhibrx-inc , Nasdaq , Media-contact , Inhibrx-inc- ,

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today...

United-states , Chiesi-farmaceutici , Bristol-myers-squibb , Prnewswire-inhibrx-inc , European-commission , Drug-administration , Inhibrx-inc , Nasdaq , Exchange-commission , Approval-program , European-medicines-agency , Oxford-finance

Inhibrx Announces Participation in Upcoming Scientific Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

Colorado , United-states , Boston , Massachusetts , Canada , Vancouver , British-columbia , American , Bryan-becklund , Vivek-subbiah , Pharmacometrics-aco , Robin-lewisl-jones

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

United-states , Bristol-myers-squibb , Exchange-commission , Prnewswire-inhibrx-inc , Inhibrx-inc , Nasdaq , Annual-report , Quarterly-reports , Current-reports , Private-securities-litigation-reform-act , Media-contact , Inhibrx-inc-

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today...

United-states , Mark-lappe , Bristol-myers-squibb , Prnewswire-inhibrx-inc , European-commission , Inhibrx-inc , Nasdaq , Exchange-commission , European-union , European-medicines-agency , Inhibrx-chief-executive-officer , Fast-track